Logo
x

Search

Subscribe Now

Celiac Disease

Takeda Exercises its Exclusive Option to Acquire PvP Biologics for ~$330M

Takeda Exercises its Exclusive Option to Acquire PvP Biologics for ~$330M

  • February 26, 2020
Takeda Acquires Exclusive Worldwide License Rights for COUR's CNP-101 to Treat Celiac Disease

Takeda Acquires Exclusive Worldwide License Rights for COUR's CNP-101 to Treat Celiac Disease

  • October 22, 2019
Innovate Initiates its Dosing For P-III CeD LA 3001 Trial for Celiac Disease

Innovate Initiates its Dosing For P-III CeD LA 3001 Trial for Celiac Disease

  • August 13, 2019
Innovate Biopharmaceuticals Initiates P-III Clinical Study for Celiac Disease

Innovate Biopharmaceuticals Initiates P-III Clinical Study for Celiac Disease

  • June 10, 2019
Innovate and Massachusetts General Hospital Collaborates to Develop Larazotide for Alcoholic Liver Disease

Innovate and Massachusetts General Hospital Collaborates to Develop Larazotide for Alcoholic Liver Disease

  • December 5, 2018
Amgen Out-Licenses its AMG 714 (PRO-015) Candidate to Provention to Treat Celiac Disease

Amgen Out-Licenses its AMG 714 (PRO-015) Candidate to Provention to Treat Celiac Disease

  • November 5, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.